Bexsero Vaccine
Bexsero is a vaccine developed to protect against invasive meningococcal disease caused by Neisseria meningitidis group B. It is used to immunize infants, children, adolescents, and adults against this potentially life-threatening bacterial infection. Meningococcal disease can lead to serious complications like meningitis and sepsis.

Pharmaceutical Properties
Bexsero is a multi-component vaccine containing four key antigens derived from Neisseria meningitidis serogroup B strains:

• NHBA (Neisserial heparin binding antigen)

• fHbp (factor H binding protein)

• NadA (Neisseria adhesin A)

• PorA P1.4 (from outer membrane vesicles)

These components are highly purified and combined with an aluminum-based adjuvant to enhance the immune response. The vaccine is administered intramuscularly, usually in the thigh for infants and in the upper arm for older children and adults.

Indications for Use
Bexsero is indicated for active immunization against invasive meningococcal disease caused by Neisseria meningitidis group B.

It is recommended for:

• Infants as young as 2 months

• Children and adolescents

• Adults at increased risk of meningococcal B exposure

It may also be advised for individuals during outbreaks or before travel to high-risk areas.

Mechanism of Action
Bexsero works by introducing specific proteins found on the surface of Neisseria meningitidis group B bacteria into the body. These proteins trigger the immune system to produce antibodies and memory immune cells.

If the vaccinated individual is later exposed to the real bacteria, the immune system quickly recognizes and destroys it, preventing illness. The inclusion of multiple antigens in Bexsero allows for broader coverage against diverse strains of meningococcal B bacteria.

Clinical Protocol in Dubai
In Dubai, the administration of Bexsero follows guidelines aligned with global best practices and recommendations from the UAE Ministry of Health. The typical vaccination schedule is:

For infants (starting at 2 months of age)

• First dose: At 2 months

• Second dose: At 4 months

• Booster dose: At 12 months

For children over 12 months and adolescents

• Two doses given at least one month apart

• Booster dose may be advised after 12 months, depending on risk level

The vaccine can be co-administered with other routine childhood vaccines, but may increase the risk of fever, especially in younger infants.

Other Characteristics
Bexsero is generally well-tolerated. Common side effects include:

• Redness, pain, or swelling at the injection site

• Fever, especially in infants

• Fussiness, drowsiness, or loss of appetite in young children

Fever may be more pronounced when Bexsero is given with other vaccines, so paracetamol may be recommended after administration. Severe allergic reactions are extremely rare but require immediate medical attention.

Conclusion
Bexsero is an important vaccine that helps protect individuals, especially infants and young children, from the serious and potentially fatal complications of meningococcal group B disease. In Dubai, the vaccine is available as part of preventive healthcare measures, and is often included in early childhood immunization plans. Timely administration of Bexsero can provide life-saving protection, and parents are encouraged to consult their healthcare providers to ensure their child receives it on schedule.